share_log

Stryker Co. (NYSE:SYK) Shares Purchased by Tectonic Advisors LLC

Stryker Co. (NYSE:SYK) Shares Purchased by Tectonic Advisors LLC

史賽克股份有限公司(紐約證交所代碼:SYK)由構造顧問有限責任公司購買的股票
Financial News Live ·  2023/02/02 17:12

Tectonic Advisors LLC increased its position in shares of Stryker Co. (NYSE:SYK – Get Rating) by 16.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,503 shares of the medical technology company's stock after purchasing an additional 215 shares during the quarter. Tectonic Advisors LLC's holdings in Stryker were worth $304,000 as of its most recent SEC filing.

Structure Advisors LLC最近提交給美國證券交易委員會(Securities&Exchange Commission)的Form 13F文件顯示,該公司第三季度將Stryker Co.(NYSE:SYK-GET評級)的股票頭寸增加了16.7%。該公司在本季度額外購買了215股後,擁有1,503股這家醫療技術公司的股票。截至最近提交給美國證券交易委員會的文件,Structure Advisors LLC持有的Stryker股份價值30.4萬美元。

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Ontario Teachers Pension Plan Board lifted its holdings in shares of Stryker by 87,902.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company's stock worth $555,482,000 after purchasing an additional 2,075,371 shares during the period. Clearbridge Investments LLC lifted its holdings in Stryker by 664.0% in the second quarter. Clearbridge Investments LLC now owns 2,199,253 shares of the medical technology company's stock valued at $437,497,000 after acquiring an additional 1,911,376 shares during the period. TD Asset Management Inc. lifted its holdings in Stryker by 76.6% in the second quarter. TD Asset Management Inc. now owns 1,364,821 shares of the medical technology company's stock valued at $271,504,000 after acquiring an additional 592,179 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Stryker by 126.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 694,478 shares of the medical technology company's stock valued at $185,669,000 after acquiring an additional 388,467 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Stryker by 17.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,437,580 shares of the medical technology company's stock valued at $384,336,000 after acquiring an additional 213,582 shares during the period. Institutional investors and hedge funds own 77.10% of the company's stock.

其他一些機構投資者和對衝基金最近也調整了對SYK的持股。安大略省教師養老金計劃委員會在第一季度增持了87,902.2%的Stryker股票。安大略省教師養老金計劃委員會現在擁有這家醫療技術公司的2,077,732股股票,價值555,482,000美元,在此期間額外購買了2,075,371股票。ClearBridge Investments LLC在第二季度增持了664.0%的Stryker股份。ClearBridge Investments LLC現在擁有這家醫療技術公司2,199,253股股票,價值437,497,000美元,在此期間又購買了1,911,376股。道明資產管理公司在第二季度增持了76.6%的Stryker股份。TD Asset Management Inc.在此期間增持了592,179股,目前持有這家醫療技術公司1,364,821股股票,價值271,504,000美元。ArrowStreet Capital Limited Partnership在第一季度增持了126.9%的Stryker股份。ArrowStreet Capital Limited Partnership現在擁有這家醫療技術公司694,478股股票,價值185,669,000美元,在此期間又購買了388,467股。最後,高盛股份有限公司在第一季度增持了史賽克17.4%的股份。高盛股份有限公司在此期間增持了213,582股,目前持有這家醫療技術公司1,437,580股股票,價值384,336,000美元。機構投資者和對衝基金持有該公司77.10%的股票。

Get
到達
Stryker
史崔克
alerts:
警報:

Insider Activity

內幕活動

In related news, VP M Kathryn Fink sold 6,571 shares of the firm's stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the transaction, the vice president now owns 9,264 shares in the company, valued at approximately $2,387,240.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Srikant M. Datar sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 7th. The stock was sold at an average price of $240.25, for a total transaction of $240,250.00. Following the transaction, the director now owns 6,262 shares in the company, valued at approximately $1,504,445.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 6,571 shares of the stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total value of $1,693,280.99. Following the sale, the vice president now directly owns 9,264 shares of the company's stock, valued at $2,387,240.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,139 shares of company stock worth $19,150,115. 6.70% of the stock is currently owned by insiders.

在相關新聞中,副總裁凱瑟琳·芬克在1月11日星期三的一次交易中出售了6571股該公司的股票。股票以257.69美元的平均價格出售,總成交金額為1,693,280.99美元。交易完成後,副總經理總裁現在擁有該公司9264股,價值約2387,240.16美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在這個環節。在相關新聞中,董事在12月7日星期三的一次交易中出售了1,000股該公司的股票。該股以240.25美元的平均價格出售,總成交金額為240,250.00美元。交易完成後,董事現在擁有該公司6,262股股份,價值約1,504,445.50美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在這個環節。此外,副總裁M凱瑟琳·芬克在1月11日星期三的一筆交易中出售了6571股該股。這隻股票的平均售價為257.69美元,總價值為1,693,280.99美元。出售股份後,總裁副手現在直接持有該公司9264股股票,價值2387,240.16美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士出售了79,139股公司股票,價值19,150,115美元。該公司6.70%的股份目前由內部人士持有。

Stryker Price Performance

Stryker價格表現

Shares of NYSE SYK opened at $280.70 on Thursday. Stryker Co. has a 1-year low of $188.84 and a 1-year high of $281.45. The company has a market cap of $106.23 billion, a price-to-earnings ratio of 45.21, a price-to-earnings-growth ratio of 2.83 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.04 and a quick ratio of 1.19. The stock's 50-day moving average is $246.81 and its two-hundred day moving average is $225.74.
紐約證交所SYK股價週四開盤報280.70美元。Stryker Co.的股價為一年低點188.84美元,一年高點為281.45美元。該公司市值為1,062.3億美元,市盈率為45.21倍,市盈率為2.83倍,貝塔係數為0.93。該公司的債務權益比為0.77,流動比率為2.04,速動比率為1.19。該股的50日移動均線切入位在246.81美元,200日移動均線切入位在225.74美元。

Stryker (NYSE:SYK – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The medical technology company reported $3.00 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.16. Stryker had a return on equity of 22.70% and a net margin of 12.78%. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the business posted $2.71 EPS. The business's revenue for the quarter was up 10.7% on a year-over-year basis. Analysts forecast that Stryker Co. will post 9.83 EPS for the current fiscal year.

Stryker(紐約證券交易所代碼:SYK-GET Rating)最近一次發佈季度收益數據是在1月31日星期二。這家醫療技術公司公佈本季度每股收益為3.00美元,比分析師普遍預期的2.84美元高出0.16美元。Stryker的股本回報率為22.70%,淨利潤率為12.78%。該業務本季度營收為52億美元,而市場普遍預期為49.7億美元。在去年同一季度,該業務公佈的每股收益為2.71美元。該業務當季營收較上年同期增長10.7%。分析師預計,Stryker Co.本財年每股收益將達到9.83歐元。

Stryker Increases Dividend

Stryker增加股息

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, January 31st. Stockholders of record on Friday, December 30th were issued a $0.75 dividend. The ex-dividend date of this dividend was Thursday, December 29th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.07%. This is an increase from Stryker's previous quarterly dividend of $0.70. Stryker's dividend payout ratio is presently 48.62%.

該公司最近還披露了季度股息,股息於1月31日(星期二)支付。12月30日星期五,登記在冊的股東獲得了0.75美元的股息。本次股息除息日期為12月29日星期四。這意味着年化股息為3.00美元,股息收益率為1.07%。這比Stryker之前0.70美元的季度股息有所增加。Stryker的股息支付率目前為48.62%。

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

SYK has been the subject of a number of recent analyst reports. Cowen boosted their price objective on Stryker from $233.00 to $283.00 in a research report on Wednesday, December 14th. Evercore ISI boosted their price target on Stryker to $265.00 in a research report on Tuesday, January 3rd. Canaccord Genuity Group boosted their price target on Stryker from $220.00 to $250.00 and gave the stock a "hold" rating in a research report on Wednesday. Robert W. Baird boosted their price target on Stryker from $240.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Loop Capital upped their target price on Stryker from $245.00 to $290.00 and gave the company a "buy" rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and a consensus price target of $271.32.

SYK是最近多份分析師報告的主題。考恩在12月14日星期三的一份研究報告中將他們對Stryker的目標價從233.00美元上調至283.00美元。1月3日,Evercore ISI在一份研究報告中將他們對Stryker的目標價上調至265.00美元。在週三的一份研究報告中,Cancord Genuity Group將Stryker的目標價從220.00美元上調至250.00美元,並給予該股“持有”評級。週三,羅伯特·W·貝爾德在一份研究報告中將Stryker的目標價從240.00美元上調至287.00美元,並給予該股“跑贏大盤”的評級。最後,Loop Capital在週三的一份報告中將Stryker的目標價從245.00美元上調至290.00美元,並給予該公司“買入”評級。7名研究分析師對該股的評級為持有,14名分析師對該股的評級為買入。根據MarketBeat的數據,Stryker目前的共識評級為“適度買入”,共識目標價為271.32美元。

Stryker Company Profile

Stryker公司簡介

(Get Rating)

(獲取評級)

Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries.

Stryker Corp.是一家醫療技術公司。它通過以下部門開展業務:整形外科和脊柱以及醫學外科和神經技術。骨科和脊柱部門提供用於全關節置換的植入物,如髖關節、膝蓋和肩部,以及創傷和四肢手術。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Stryker (SYK)
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • Apple's Earnings, Expectations and Surprises
  • T-Mobile Delivers Where it Matters Most to Investors
  • Exxon Mobil Could Gush To New Highs Very Soon
  • 免費獲取StockNews.com關於Stryker的研究報告(SYK)
  • Meta平臺的底部已經到了,波動性還沒有結束
  • 阿拉斯加航空公司近期收益分析
  • 蘋果的收益、預期和驚喜
  • T-Mobile在對投資者最重要的領域提供服務
  • 埃克森美孚可能很快創下新高

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

接受Stryker Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Stryker和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論